Acer Medical Inc. is strengthening its portfolio of AI-assisted medical devices, expanding beyond its flagship AI ophthalmology screening software. The company is now advancing into chest X-ray imaging for bone density abnormality detection and accelerating development in AI-assisted kidney disease diagnostics. This strategic expansion aims to broaden clinical adoption of its AI-powered medical imaging solutions.

As generative AI (GenAI) continues to evolve, Acer Medical Inc. is actively assessing its role in healthcare’s digital transformation. The company is strategizing on developing specialized GenAI models across different medical specialties. By collaborating with medical institutions on research and development, followed by technology transfer and regulatory approvals, Acer Medical Inc. aims to commercialize GenAI-based solutions that enhance global healthcare capabilities while driving future business growth.

Currently, Acer Medical Inc.'s VeriSee series of AI-assisted screening software has obtained 13 certifications, reached 11 countries and regions, and has been deployed in over 300 medical institutions. In the past year, the company achieved a revenue milestone of NT$50 million, marking an 80% year-over-year growth and setting a new record.

According to Chairman Allen Lien, the company’s revenue growth is attributed to years of strategic expansion in Taiwan and successful penetration into Southeast Asian healthcare markets. Notably, Thailand has demonstrated significant contribution to overseas growth, while Malaysia and Indonesia—where public health initiatives are gaining momentum—also show promising potential.

GenAI applications are increasingly gaining traction in healthcare, with major medical centers integrating AI-driven solutions.Lien highlighted that AI adoption is evolving from predictive AI toward GenAI, focusing on hospital-centric AI system deployment. Acer Medical Inc. is embracing the “One Specialty, One AI” approach, leveraging extensive clinical data to provide more precise diagnostic support.

Moving forward, Acer Medical Inc. is actively collaborating with various medical departments in top-tier hospitals. Upon successful research, technology transfer, and commercialization, the company plans to secure regulatory approvals and expand internationally. By leveraging its expertise in AI healthcare technologies, Acer Medical Inc. aims to extend its impact on the global medical landscape.

Resource:宏碁智醫拚轉型 布局GenAI